Comprehensive Cancer Care for the Doral Community
-
By
-
June 2, 2026
-
2 min
By
June 2, 2026
At the ASCO annual meeting, Dana-Farber’s Brian Wolpin, MD, MPH, presented positive results from the RASolute 302 trial showing a substantial prolongation of survival for patients with previously treated metastatic pancreatic cancer, regardless of RAS mutation status, taking daraxonrasib, an investigational oral RAS(ON) multi-selective inhibitor, compared with chemotherapy.
June 1, 2026
by Bing Guo, Ge Zhang, Shengpeng Sang, Xianfen Ma, Huanpeng Qi
June 2, 2026